PAREXEL - Thomas Senderovitz speaks about PAREXEL's global capabilities
We are clearly seeing an increased focus on early patient access. It seems very clear to us that studies in patients already starting in first in human studies very rapidly thereafter is an increasing trend globally. The earlier you go into patients and the target populations, the earlier you can really learn about whether your potential medicine actually is effective and safe or not. Earlier access to patients and also increased use of biomarkers globally, is a clear trend that we see. PAREXEL has a unique global network of sites and expertise to address trends by accessing patients early. We have five in-house clinical Phase I units in which we can also study patients. In addition, we have world leading expertise in accessing patients out in hospitals at unique clinical sites. By doing that and utilizing our unique expertise in translational medicine and biomarkers, we can help Japanese companies in addressing these trends.